Company profile
Polaris Genomics company profile
Polaris Genomics is mapping molecular biomarkers to chart a new course for objective mental health diagnostics and novel therapeutics. Polaris Genomics identifies genomic biomarkers to support the development of psychiatric drugs and clinical tools. The company's genomics-based ADAPT Platform™ curates information on biologically-relevant gene network pathways indicated in neuropsychiatric conditions — including anxiety, depression, alcohol/substance use disorder, ADHD, PTSD, and TBI (ADAPT). The ADAPT Platform™ comprises: 1. targeted neuropsychiatric gene panel, which contains 1000+ transcriptomic biomarkers related to known system pathways in neuropsychiatric conditions; 2. deep analytics (AI/ML) engine; and 3. expanding data lake and sample repository. ADAPT has identified transcriptomic biomarkers for PTSD, resulting in the first-of-its-kind clinical blood test for PTSD screening, Polaris' PTS-ID™.
Business identity
- Website
- http://polarisgenomics.com/
- Contact email
- [email protected]
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 11-50 employees
- Revenue range
- $0+
- Founded
- 2017-01-01, Year
Headquarters
- Headquarters
- Gaithersburg, Maryland, United States
- Country code
- US
- Continent
- North America